Deepti Duvvuru et al.
FULL PAPERS
[5] For other methods, see: a) M. Westling, T. Livinghouse,
J. Am. Chem. Soc. 1987, 109, 590–592; b) K. N. Clary,
M. Parvez, T. G. Back, J. Org. Chem. 2010, 75, 3751–
3760.
[6] For recent reviews on phosphine promoted annulation
reactions, see: a) X. Lu, C. Zhang, Z. Xu, Acc. Chem.
Res. 2001, 34, 535–544; b) J. L. Methot, W. R. Roush,
Adv. Synth. Catal. 2004, 346, 1035–1050; c) L.-W. Ye, J.
Zhou, Y. Tang, Chem. Soc. Rev. 2008, 37, 1140–1152;
d) B. J. Cowen, S. J. Miller, Chem. Soc. Rev. 2009, 38,
3102–3116; e) C. Nꢅjera, J. M. Sansano, M. Yus, J.
Braz. Chem. Soc. 2010, 21, 377–412; f) A. Marinetti,
A. Voituriez, Synlett 2010, 174–194.
Computational Methods
Geometry optimization was carried out at the B97-D level
of theory[17] with the def2-TZVPP basis set.[18] These calcula-
tions were accelerated using the Multipole Accelerated Res-
olution of Identity for
J
(MARI-J) approximation
method,[19] as implemented in Turbomole 6.2.[20] LUMO
have been drawn using the gOpenMol 3.00 package.[21] The
molecular orbital coefficients have been computed at the
HF/STO-3G level, based on the DFT gas-phase geome-
tries.[16c] Hꢂckel calculations were carrried out with the
Hꢂckel simple program.[22]
[7] M. Schuler, D. Duvvuru, P. Retailleau, J.-F. Betzer, A.
Marinetti, Org. Lett. 2009, 11, 4406–4409.
Acknowledgements
[8] For other synthetic approaches to pyrrolines by phos-
phine organocatalysis, see: a) Z. Xu, X. Lu, Tetrahe-
dron Lett. 1997, 38, 3461–3464; b) Z. Xu, X. Lu, J.
Org. Chem. 1998, 63, 5031–5041; c) M. Shi, Y.-M. Xu,
Eur. J. Org. Chem. 2002, 696–701; d) X.-F. Zhu, C. E.
Henry, O. Kwon, Tetrahedron 2005, 61, 6276–6282;
e) S. Castellano, H. D. G. Fiji, S. S. Kinderman, M. Wa-
tanabe, P. de Leon, F. Tamanoi, O. Kwon, J. Am. Chem.
Soc. 2007, 129, 5843–5845; f) B. Zhang, Z. He, S. Xu,
G. Wu, Z. He, Tetrahedron 2008, 64, 9471–9479; g) N.
Fleury-Brꢀgeot, L. Jean, P. Retailleau, A. Marinetti,
Tetrahedron 2007, 63, 11920–11927; h) Y.-Q. Fang and
E. N. Jacobsen, J. Am. Chem. Soc. 2008, 130, 5660–
5661; i) N. Pinto, N. Fleury-Brꢀgeot, A. Marinetti, Eur.
J. Org. Chem. 2009, 146–151.
[9] X. Fu, S. Zhang, J. Yin, T. L. McAllister, S. A. Jiang,
C.-H. Tann, T. K. Thiruvengadam, F. Zhang, Tetrahe-
dron Lett. 2002, 43, 573–576.
[10] CCDC 786106 contains the supplementary crystallo-
graphic data for this compound. These data can be ob-
tained free of charge from The Cambridge Crystallo-
request/cif or from CCDC, 12 Union Road, Cambridge
CB2 1EZ, UK (fax (+44) 1223–336033; e-mail:
deposit@ccdc.cam.uk).
[11] Portionwise addition of the phosphine, that is, 15–
20 mol% at the beginning of the reaction and again
after 8 h heating, can be applied to increase conversion
rates.
[12] E. Piers, J. R. Grierson, C. K. Lau, I. Nagakura, Can. J.
Chem. 1982, 60, 210–223.
[13] A. B. Pulipaka, S. C. Bergmeier, J. Org. Chem. 2008,
73, 1462–1467.
[14] a) Y.-L. Shi, Y.-M. Xu, M. Shi, Adv. Synth. Catal. 2004,
346, 1220–1230; b) Y.-L. Shi, M. Shi, Tetrahedron 2006,
62, 461–475; c) V. Declerck, J. Martinez, F. Lamaty,
Chem. Rev. 2009, 109, 1–48.
We are grateful to ICSN and to the Agence Nationale de la
Recherche (ANR) for financial support. This work has been
done within the PhoSciNet COST action.
References
[1] For recent representative examples, see: a) T. J.
Watson, T. A. Ayers, N. Shah, D. Wenstrup, M. Web-
ster, D. Freund, S. Horgan, J. P. Carey, Org. Process
Res. Dev. 2003, 7, 521–532; b) P.-P. Kung, B. Huang, G.
Zhang, J. Z. Zhou, J. Wang, J. A. Digits, J. Skaptason,
S. Yamazaki, D. Neul, M. Zientek, J. Elleraas, P.
Mehta, M.-J. Yin, M. J. Hickey, K. S. Gajiwala, C.
Rodgers, J. F. Davies II, M. R. Gehring, J. Med. Chem.
2010, 53, 499–503; c) S. Van Goethem, P. Van der Vek-
en, V. Dubois, A. Soroka, A.-M. Lambeir, X. Chen, A.
Haemers, S. Scharpꢀ, I. De Meester, K. Augustyns,
Bioorg. Med. Chem. Lett. 2008, 18, 4159–4162.
[2] a) D. Achard, S. Grisoni, E. James-Surcouf, J.-L. Mal-
leron, A. Morgat, J.-F. Peyronel, J.-F. Sabuco, M.
Tabart, (Rhꢄne–Poulenc Rorer S.A.), Patent WO 95/
04040, 1995; b) J.-D. Bourzat, A. CommerÅon, N.
Dereu, P. Mailliet, F. Sounigo-Thompson, J.-P. Martin,
M. Capet, M. Cheve, (Rhꢄne Poulenc-Rorer S.A.),
Patent WO98/29390, 1998; c) P. Mailliet, C. Salagnad,
(Aventis Pharma S.A.), Patent WO01/07408, 2001; d) F.
Gasparini, Y. Auberson, S. Ofner, (Novartis Pharma
GMBH), Patent WO03/047581, 2003; e) V. J. Santora,
J. A. Covel, R. Hayashi, R. R. Webb, A. S. Ren, W. G.
Chen, J. J. Duffield, J. B. Ibarra, M. Pulley, G. Semple,
M. I. Weinhouse, (Arena Pharmaceuticals), Patent WO
2007/061741, 2007; f) M. Ogata, H. Matsumoto, S. Shi-
mizu, S. Kida, H. Nakai, K. Motokawa, H. Miwa, S.
Matsuura, T. Yoshida, Eur. J. Med. Chem. 1991, 26,
889–906.
[15] Only b-unsubstituted cyclic enones are common sub-
strates for aza-Morita–Baylis–Hillman reactions: M.
Shi, Y.-M. Xu, Chem. Commun. 2001, 1876–1877.
[16] a) Y. Xia, Y. Liang, Y. Chen, M. Wang, L. Jiao, F.
Huang, S. Liu, Y. Li, Z.-X. Yu, J. Am. Chem. Soc. 2007,
129, 3470–3471; b) E. Mercier, B. Fonovic, C. Henry,
O. Kwon, T. Dudding, Tetrahedron Lett. 2007, 48,
3617–3620; c) Y. Liang, S. Liu, Y. Xia, Y. Li, Z.-X. Yu,
Chem. Eur. J. 2008, 14, 4361–4373.
[3] a) K. Popandova-Yambolieva, C. Ivanov, Synth.
Commun. 1986, 16, 57–61; b) J.-L. Malleron, J.-F. Peyr-
onel, P. Desmazeau, C. M’Houmadi, C. Planiol, Tetra-
hedron Lett. 1995, 36, 543–546; c) D. Bonnet-Delpon,
J.-P. Bꢀguꢀ, T. Lequeux, M. Ourevitch, Tetrahedron
1996, 52, 59–70.
[4] a) S. Mutti, C. Daubiꢀ, J. Malpart, X. Radisson, Tetra-
hedron Lett. 1996, 37, 8743–8746; b) H. Okamura, H.
Shimizu, Y. Nakamura, T. Iwagawa, M. Nakatani, Tet-
rahedron Lett. 2000, 41, 4147–4150.
[17] S. Grimme, J. Comput. Chem. 2006, 27, 1787–1799.
492
ꢁ 2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Adv. Synth. Catal. 2011, 353, 483 – 493